CTOs on the Move


 
Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.janpixbio.com
  • One Broadway, 14th Floor
    Cambridge, MA USA 02142
  • Phone: 617.956.2803

Executives

Name Title Contact Details

Funding

Janpix raised $10M on 10/07/2020

Similar Companies

Biolog

Biolog is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NatureWorks

NatureWorks LLC is a stand-alone company wholly owned by Cargill. Dedicated to meeting the world's needs today without compromising the earth's ability to meet the needs of tomorrow, NatureWorks LLC is the first company to offer a family of commercially

Kiniciti

Empowering the industry with the resources, expertise, and capital to help accelerate the advancement and adoption of cell and gene therapies.

Surface Logix

Surface Logix, Inc. is a Brighton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cell Signaling Technology

Cell Signaling Technology, Inc. is a Danvers, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.